MedTrace Logo

Postpartum Screening for Anxiety and Comorbid Conditions

NCT06242717 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2024-02-23

No results posted yet for this study

Summary

The goal of this project is to facilitate the design of individualized postpartum anxiety (PPA) screening strategies in British Columbia (BC), Canada. A cohort of postpartum people (n=550) will be invited to complete the following seven questionnaires at 4-8 weeks after delivery:

1. State-Trait Anxiety Inventory
2. Edinburgh Postnatal Depression Scale
3. Multidimensional Scale of Perceived Social Support
4. PROMIS (Patient-Reported Outcomes Measurement Information System) Emotional Distress-Anger, Short Form 5-a
5. Short Form Brief Pain Inventory
6. WHOQOL-BREF for assessing quality of life
7. PROMIS Sleep Disturbance Short Form 8-b and PROMIS Sleep-Related Impairment Short Form 8-a

The investigators will evaluate the feasibility of screening for postpartum anxiety and comorbid conditions through a web-based platform in a diverse BC population. They will assess the usability of the platform and questionnaires through 12-15 follow-up interviews with study participants and responses to the System Usability Scale. Their analysis will also identify patient characteristics and comorbidities (e.g., anger, pain, sleep disturbance) associated with a positive screen for postpartum anxiety.

Conditions

  • Postpartum Anxiety
  • Postpartum Depression
  • Postpartum Disorder
  • Postoperative Pain
  • Sleep Wake Disorders
  • Quality of Life
  • Anger

Sponsors & Collaborators

  • Ministry of Health, British Columbia

    collaborator OTHER_GOV

  • Providence Healthcare

    collaborator OTHER

  • St. Paul's Hospital, Canada

    collaborator OTHER

  • University of Victoria

    collaborator OTHER

  • Stanford University

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06242717 on ClinicalTrials.gov